ENZO THERAPEUTICS, INC.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
 
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 21234
 
 
 
C07K PEPTIDES 4132
 
 
 
C07C ACYCLIC OR CARBOCYCLIC COMPOUNDS 3135
 
 
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 396
 
 
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 3164
 
 
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 293
 
 
 
A61N ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY 2105
 
 
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 247
 
 
 
C07D HETEROCYCLIC COMPOUNDS 2160
 
 
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 2123

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2018/0042,959 GLUCOCEREBROSIDE TREATMENT OF DISEASEJun 12, 17Feb 15, 18[A61K]
2018/0036,326 METHOD FOR TREATING HIVOct 11, 17Feb 08, 18[A61K]
2018/0037,648 METHODS FOR TREATING MELANOMAOct 11, 17Feb 08, 18[A61N, A61K, C07K]

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9907810 Glucocerebroside treatment of liver disordersJul 12, 17Mar 06, 18[A61K]
9744185 Glucocerebroside treatment of liver disordersMar 17, 06Aug 29, 17[A61K]
9717754 Glucocerebroside treatment of diseaseSep 30, 03Aug 01, 17[A61K]
9421257 Methods for modulating Th1/Th2 cell balance by increasing leptin activityJan 16, 15Aug 23, 16[A61N, A61K, C07K]
9388121 Sphingosine kinase type 1 inhibitorsOct 11, 12Jul 12, 16[C07D, C07C, A61K]
8969291 Methods for decreasing leptin levels or activity for treating inflammationSep 07, 10Mar 03, 15[A61K]
8758759 Transmucosal administration of aggregated antigensOct 17, 03Jun 24, 14[A61K]
8703480 Biological function effecting viral vectors and chimeric cells useful as packaging cell lines and target cellsJan 14, 98Apr 22, 14[A61K]
8609821 Antibodies against APRIL as biomarkers for early prognosis of lymphoma patientsSep 22, 06Dec 17, 13[C07K]
8592394 Synthetic derivatives beta glycolipids and compositions thereof for the treatment of pathologic disordersOct 13, 09Nov 26, 13[A01N, A61K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2017/0042,921 METHOD FOR TREATING HIVAbandonedOct 11, 16Feb 16, 17[A61K]
2016/0319,015 LEPTIN IN IMMUNE MODULATIONAbandonedJul 07, 16Nov 03, 16[A61K, C07K]
2009/0263,895 Cell line for producing a non-retroviral vectorAbandonedMar 12, 08Oct 22, 09[C12N]
2008/0108,139 COMPOSITION OF MATTER COMPRISING PRIMARY NUCLEIC ACID COMPONENTAbandonedOct 30, 07May 08, 08[C12N, C07H]
2007/0037,284 Vectors for expressing exogenous gene or exogenous nucleic acid sequencesAbandonedNov 22, 05Feb 15, 07[C12N]
2006/0183,228 Viral vectors with surface or envelope componentsAbandonedSep 28, 05Aug 17, 06[C12N]
2005/0255,454 Novel therapeutic processes for enhancing immunized states of vaccinated subjectsAbandonedDec 08, 03Nov 17, 05[C12Q, A61K]
2005/0053,926 Nucleic Acid displacer compositions and cells comprising sameAbandonedJul 03, 01Mar 10, 05[C12Q]
2004/0171,522 Regulation of immune responses by manipulation of intermediary metabolite levelsAbandonedFeb 27, 03Sep 02, 04[A61K]
2004/0171,526 Regulation of immune responses by manipulation of intermediary metabolite levelsAbandonedDec 10, 03Sep 02, 04[A61K]
2004/0171,527 Regulation of immune responses by manipulation of intermediary metabolite levelsAbandonedDec 10, 03Sep 02, 04[A61K]
2004/0171,528 Regulation of immune responses by manipulation of intermediary metabolite levelsAbandonedDec 10, 03Sep 02, 04[A61K]
2004/0087,485 Educated nkt cells and their uses in the treatment of immune-related disordersAbandonedDec 16, 03May 06, 04[A61K]
2004/0022,768 Process useful for producing selective immune down regulation (SIDR) in subjects, including adult subjects to artificially expressed gene, gene delivery systems, infectious agents, and non-cellular immunogenic components, and processes for producing immunological tolerance in subjets using SIDRAbandonedMar 04, 03Feb 05, 04[A61K]
2004/0023,909 Process for preventing or reducing undesirable immunological effects to infectious agents in subjectsAbandonedMar 04, 03Feb 05, 04[A61K]
2003/0170,258 Novel processes implementing selective immune down regulation (SIDR)AbandonedMar 12, 03Sep 11, 03[A61K]
2001/0007,153 SOLID CHIMERIC ORGANS, ANIMAL MODELS HAVING SAME, PROCESS FOR PREPARING SAME, NON-TUMORIGENIC IMMORTALIZED HUMAN CELL LINES, SUSCEPTIBLE CELLS AND CYTOPATHIC MAMMALIAN VIRUSESAbandonedJun 16, 97Jul 05, 01[A01K]
4849208 Detectable molecules, method of preparation and useExpiredApr 28, 87Jul 18, 89[A61K]
4767609 Therapeutic and diagnostic processes using isotope transfer to chelator-target recognition molecule conjugateExpiredJan 23, 87Aug 30, 88[A61K]
4707352 Method of radioactively labeling diagnostic and therapeutic agents containing a chelating groupExpiredJan 30, 84Nov 17, 87[A61K]

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.